AQUILO CAPITAL MANAGEMENT, LLC Holdings

AQUILO CAPITAL MANAGEMENT, LLC is an investment fund managing more than 277.43M US dollars. The largest holdings include Arrowhead Pharmaceuticals, SPDR S&P Biotech ETF and Blueprint Medicines. In Q3 2022 the fund bought assets of total value of 14.01M US dollars and sold assets of total value of 12.96M US dollars.

$277.42M

portfolio value

+5.33%

quarter

-71.23%

1 year

-257.95%

3 years

AQUILO CAPITAL MANAGEMENT, LLC portfolio changes

Portfolio changes (number of shares)
Period	Buy	Sel
Q3 2018	25482000	14357000
Q4 2018	15682000	34701000
Q1 2019	18909000	2518000
Q2 2019	20251000	16323000
Q3 2019	-7902000	37249000
Q4 2019	72684000	8736000
Q1 2020	44732000	12940000
Q2 2020	112474000	26329000
Q3 2020	45695000	73465000
Q4 2020	31435000	57782000
Q1 2021	77568000	46023000
Q2 2021	39437000	19832000
Q3 2021	78972000	43241000
Q4 2021	72492000	28213000
Q1 2022	-46031000	13977000
Q2 2022	-72512000	34262000
Q3 2022	14008000	12956000

AQUILO CAPITAL MANAGEMENT, LLC 13F holdings

Stock	Position type	Portfolio share	Portfolio value	Avg. open price	Current price	P/L	Last change
Biotechnology Arrowhead Pharmaceuticals, Inc. Portfolio share: 14.52% Portfolio value: 40.27M Avg. open price: $59.41 Current price: $31.87 P/L: -46.36% Bought +1.67% shares Q3 2022	share	14.52%	40.27M	$59.41	$31.87	-46.36%	Bought +1.67% shares Q3 2022
SPDR S&P Biotech ETF Portfolio share: 14.30% Portfolio value: 39.66M Avg. open price: $95.35 Current price: $82.88 P/L: -13.08% Sold -33.33% shares Q3 2022	put	14.30%	39.66M	$95.35	$82.88	-13.08%	Sold -33.33% shares Q3 2022
Biotechnology Blueprint Medicines Corporation Portfolio share: 12.45% Portfolio value: 34.54M Avg. open price: $99.26 Current price: $50.19 P/L: -49.43% Sold -26.83% shares Q3 2022	share	12.45%	34.54M	$99.26	$50.19	-49.43%	Sold -26.83% shares Q3 2022
Biotechnology Merus N.V. Portfolio share: 10.88% Portfolio value: 30.18M Avg. open price: $27.01 Current price: $14.2 P/L: -47.42% Bought +2.03% shares Q3 2022	share	10.88%	30.18M	$27.01	$14.2	-47.42%	Bought +2.03% shares Q3 2022
Biotechnology Arvinas, Inc. Portfolio share: 10.77% Portfolio value: 29.88M Avg. open price: $78.71 Current price: $39.53 P/L: -49.78% Sold -12.96% shares Q3 2022	share	10.77%	29.88M	$78.71	$39.53	-49.78%	Sold -12.96% shares Q3 2022
Biotechnology REGENXBIO Inc. Portfolio share: 9.22% Portfolio value: 25.57M Avg. open price: $36.71 Current price: $23.04 P/L: -37.24% Sold -17.13% shares Q3 2022	share	9.22%	25.57M	$36.71	$23.04	-37.24%	Sold -17.13% shares Q3 2022
Biotechnology uniQure N.V. Portfolio share: 5.69% Portfolio value: 15.78M Avg. open price: $36.8 Current price: $25.65 P/L: -30.30% Sold -13.38% shares Q3 2022	share	5.69%	15.78M	$36.8	$25.65	-30.30%	Sold -13.38% shares Q3 2022
Drug Manufacturers—Specialty & Generic Amryt Pharma plc Portfolio share: 4.99% Portfolio value: 13.83M Avg. open price: $11.33 Current price: $7.16 P/L: -36.78% Bought +7.09% shares Q3 2022	share	4.99%	13.83M	$11.33	$7.16	-36.78%	Bought +7.09% shares Q3 2022
Biotechnology Silence Therapeutics plc Portfolio share: 4.57% Portfolio value: 12.67M Avg. open price: N/A Current price: $17.09 P/L: N/A N/A Q3 2022	share	4.57%	12.67M	N/A	$17.09	N/A	N/A Q3 2022
Biotechnology argenx SE Portfolio share: 3.05% Portfolio value: 8.47M Avg. open price: $290.99 Current price: $393.21 P/L: +35.13% Bought +8.11% shares Q1 2022	share	3.05%	8.47M	$290.99	$393.21	+35.13%	Bought +8.11% shares Q1 2022
Biotechnology Genmab A/S Portfolio share: 2.84% Portfolio value: 7.86M Avg. open price: $37.32 Current price: $46.04 P/L: +23.35% Bought +13.96% shares Q3 2022	share	2.84%	7.86M	$37.32	$46.04	+23.35%	Bought +13.96% shares Q3 2022
Biotechnology Kymera Therapeutics, Inc. Portfolio share: 2.59% Portfolio value: 7.18M Avg. open price: N/A Current price: $29.11 P/L: N/A N/A Q3 2022	share	2.59%	7.18M	N/A	$29.11	N/A	N/A Q3 2022
Biotechnology Spero Therapeutics, Inc. Portfolio share: 2.45% Portfolio value: 6.80M Avg. open price: $13.33 Current price: $1.89 P/L: -85.82% Sold -36.04% shares Q3 2022	share	2.45%	6.80M	$13.33	$1.89	-85.82%	Sold -36.04% shares Q3 2022
Biotechnology Pieris Pharmaceuticals, Inc. Portfolio share: 1.67% Portfolio value: 4.64M Avg. open price: $3.77 Current price: $0.99 P/L: -73.74% Bought +8.03% shares Q3 2022	share	1.67%	4.64M	$3.77	$0.99	-73.74%	Bought +8.03% shares Q3 2022
Biotechnology 4D Molecular Therapeutics, Inc. Portfolio share: 0.01% Portfolio value: 29K Avg. open price: $34.43 Current price: $23.17 P/L: -32.70% Sold -99.59% shares Q3 2022	share	0.01%	29K	$34.43	$23.17	-32.70%	Sold -99.59% shares Q3 2022

Showing TOP 15 AQUILO CAPITAL MANAGEMENT's 13F holdings.

Frequently Asked Questions (FAQ)

What is the biggest position of AQUILO CAPITAL MANAGEMENT, LLC?

The biggest position of the AQUILO CAPITAL MANAGEMENT, LLC is Arrowhead Pharmaceuticals, Inc. (ARWR) with 14.52% portfolio share worth of 40.27M US dollars.

Top 5 AQUILO CAPITAL MANAGEMENT's holdings represent 62.92% of the portfolio:

Arrowhead Pharmaceuticals, Inc. (ARWR) – 14.52%
SPDR S&P Biotech ETF (XBI) – 14.3%
Blueprint Medicines Corporation (BPMC) – 12.45%
Merus N.V. (MRUS) – 10.88%
Arvinas, Inc. (ARVN) – 10.77%

Who is the portfolio manager of AQUILO CAPITAL MANAGEMENT, LLC?

The portfolio manager of the AQUILO CAPITAL MANAGEMENT, LLC is .

What is the total asset value of the AQUILO CAPITAL MANAGEMENT, LLC portfolio?

AQUILO CAPITAL MANAGEMENT, LLC total asset value (portfolio value) is 277.43M US dollars.

Who is ?

is the portfolio manager of the AQUILO CAPITAL MANAGEMENT, LLC.

What is (AQUILO CAPITAL MANAGEMENT, LLC) fund performance?

AQUILO CAPITAL MANAGEMENT's quarterly performance is +5.33%, annualy -71.23%. In the past 3 years, the value of 's portfolio has decreased by -258%.

What is the AQUILO CAPITAL MANAGEMENT, LLC CIK?

AQUILO CAPITAL MANAGEMENT's Central Index Key is 0001591986 .